No Cover Image

Journal article 576 views 38 downloads

Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination

Hayley Holt Orcid Logo, David A. Jolliffe, Mohammad Talaei Orcid Logo, Sian Faustini, Giulia Vivaldi Orcid Logo, Matthew Greenig, Alex G. Richter, Ronan Lyons Orcid Logo, Christopher J. Griffiths, Frank Kee, Aziz Sheikh, Gwyneth Davies Orcid Logo, Seif O. Shaheen, Adrian R. Martineau

npj Vaccines, Volume: 8, Issue: 1

Swansea University Authors: Ronan Lyons Orcid Logo, Gwyneth Davies Orcid Logo

  • 63120.pdf

    PDF | Version of Record

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.

    Download (574.83KB)

Check full text

DOI (Published version): 10.1038/s41541-023-00614-0

Abstract

Prospective population-based studies investigating associations between reactive symptoms following SARS-CoV-2 vaccination and serologic responses to vaccination are lacking. We therefore conducted a study in 9003 adults from the UK general population receiving SARS-CoV-2 vaccines as part of the nat...

Full description

Published in: npj Vaccines
ISSN: 2059-0105
Published: Springer Science and Business Media LLC 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa63120
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2023-04-12T10:24:40Z
last_indexed 2023-04-13T03:23:51Z
id cronfa63120
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>63120</id><entry>2023-04-12</entry><title>Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination</title><swanseaauthors><author><sid>83efcf2a9dfcf8b55586999d3d152ac6</sid><ORCID>0000-0001-5225-000X</ORCID><firstname>Ronan</firstname><surname>Lyons</surname><name>Ronan Lyons</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>92d69cf8519a334ced3f55142c811d95</sid><ORCID>0000-0003-1218-1008</ORCID><firstname>Gwyneth</firstname><surname>Davies</surname><name>Gwyneth Davies</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-04-12</date><deptcode>HDAT</deptcode><abstract>Prospective population-based studies investigating associations between reactive symptoms following SARS-CoV-2 vaccination and serologic responses to vaccination are lacking. We therefore conducted a study in 9003 adults from the UK general population receiving SARS-CoV-2 vaccines as part of the national vaccination programme. Titres of combined IgG/IgA/IgM responses to SARS-CoV-2 spike (S) glycoprotein were determined in eluates of dried blood spots collected from all participants before and after vaccination. 4262 (47.3%) participants experienced systemic reactive symptoms after a first vaccine dose. Factors associating with lower risk of such symptoms included older age (aOR per additional 10 years of age 0.85, 95% CI: 0.81–0.90), male vs. female sex (0.59, 0.53–0.65) and receipt of an mRNA vaccine vs. ChAdOx1 nCoV-19 (0.29, 0.26–0.32 for BNT162b2; 0.06, 0.01–0.26 for mRNA-1273). Higher risk of such symptoms was associated with SARS-CoV-2 seropositivity and COVID-19 symptoms prior to vaccination (2.23, 1.78–2.81), but not with SARS-CoV-2 seropositivity in the absence of COVID-19 symptoms (0.94, 0.81–1.09). Presence vs. absence of self-reported anxiety or depression at enrolment associated with higher risk of such symptoms (1.24, 1.12–1.39). Post-vaccination anti-S titres were higher among participants who experienced reactive symptoms after vaccination vs. those who did not (P &lt; 0.001). We conclude that factors influencing risk of systemic symptoms after SARS-CoV-2 vaccination include demographic characteristics, pre-vaccination SARS-CoV-2 serostatus and vaccine type. Participants experiencing reactive symptoms following SARS-CoV-2 vaccination had higher post-vaccination titres of IgG/A/M anti-S antibodies. Improved public understanding of the frequency of reactogenic symptoms and their positive association with vaccine immunogenicity could potentially increase vaccine uptake.</abstract><type>Journal Article</type><journal>npj Vaccines</journal><volume>8</volume><journalNumber>1</journalNumber><paginationStart/><paginationEnd/><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2059-0105</issnElectronic><keywords>Fever, Risk factors, RNA vaccines</keywords><publishedDay>25</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-02-25</publishedDate><doi>10.1038/s41541-023-00614-0</doi><url>http://dx.doi.org/10.1038/s41541-023-00614-0</url><notes/><college>COLLEGE NANME</college><department>Health Data Science</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HDAT</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>Barts Charity</funders><projectreference/><lastEdited>2023-05-18T14:43:29.1034872</lastEdited><Created>2023-04-12T11:11:21.1169491</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Health Data Science</level></path><authors><author><firstname>Hayley</firstname><surname>Holt</surname><orcid>0000-0003-4153-7982</orcid><order>1</order></author><author><firstname>David A.</firstname><surname>Jolliffe</surname><order>2</order></author><author><firstname>Mohammad</firstname><surname>Talaei</surname><orcid>0000-0002-6901-3665</orcid><order>3</order></author><author><firstname>Sian</firstname><surname>Faustini</surname><order>4</order></author><author><firstname>Giulia</firstname><surname>Vivaldi</surname><orcid>0000-0003-0816-9276</orcid><order>5</order></author><author><firstname>Matthew</firstname><surname>Greenig</surname><order>6</order></author><author><firstname>Alex G.</firstname><surname>Richter</surname><order>7</order></author><author><firstname>Ronan</firstname><surname>Lyons</surname><orcid>0000-0001-5225-000X</orcid><order>8</order></author><author><firstname>Christopher J.</firstname><surname>Griffiths</surname><order>9</order></author><author><firstname>Frank</firstname><surname>Kee</surname><order>10</order></author><author><firstname>Aziz</firstname><surname>Sheikh</surname><order>11</order></author><author><firstname>Gwyneth</firstname><surname>Davies</surname><orcid>0000-0003-1218-1008</orcid><order>12</order></author><author><firstname>Seif O.</firstname><surname>Shaheen</surname><order>13</order></author><author><firstname>Adrian R.</firstname><surname>Martineau</surname><order>14</order></author></authors><documents><document><filename>63120__27417__7e333adbbc06445eb5ceb6105a8a79b7.pdf</filename><originalFilename>63120.pdf</originalFilename><uploaded>2023-05-10T16:12:03.2029285</uploaded><type>Output</type><contentLength>588628</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 63120 2023-04-12 Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination 83efcf2a9dfcf8b55586999d3d152ac6 0000-0001-5225-000X Ronan Lyons Ronan Lyons true false 92d69cf8519a334ced3f55142c811d95 0000-0003-1218-1008 Gwyneth Davies Gwyneth Davies true false 2023-04-12 HDAT Prospective population-based studies investigating associations between reactive symptoms following SARS-CoV-2 vaccination and serologic responses to vaccination are lacking. We therefore conducted a study in 9003 adults from the UK general population receiving SARS-CoV-2 vaccines as part of the national vaccination programme. Titres of combined IgG/IgA/IgM responses to SARS-CoV-2 spike (S) glycoprotein were determined in eluates of dried blood spots collected from all participants before and after vaccination. 4262 (47.3%) participants experienced systemic reactive symptoms after a first vaccine dose. Factors associating with lower risk of such symptoms included older age (aOR per additional 10 years of age 0.85, 95% CI: 0.81–0.90), male vs. female sex (0.59, 0.53–0.65) and receipt of an mRNA vaccine vs. ChAdOx1 nCoV-19 (0.29, 0.26–0.32 for BNT162b2; 0.06, 0.01–0.26 for mRNA-1273). Higher risk of such symptoms was associated with SARS-CoV-2 seropositivity and COVID-19 symptoms prior to vaccination (2.23, 1.78–2.81), but not with SARS-CoV-2 seropositivity in the absence of COVID-19 symptoms (0.94, 0.81–1.09). Presence vs. absence of self-reported anxiety or depression at enrolment associated with higher risk of such symptoms (1.24, 1.12–1.39). Post-vaccination anti-S titres were higher among participants who experienced reactive symptoms after vaccination vs. those who did not (P < 0.001). We conclude that factors influencing risk of systemic symptoms after SARS-CoV-2 vaccination include demographic characteristics, pre-vaccination SARS-CoV-2 serostatus and vaccine type. Participants experiencing reactive symptoms following SARS-CoV-2 vaccination had higher post-vaccination titres of IgG/A/M anti-S antibodies. Improved public understanding of the frequency of reactogenic symptoms and their positive association with vaccine immunogenicity could potentially increase vaccine uptake. Journal Article npj Vaccines 8 1 Springer Science and Business Media LLC 2059-0105 Fever, Risk factors, RNA vaccines 25 2 2023 2023-02-25 10.1038/s41541-023-00614-0 http://dx.doi.org/10.1038/s41541-023-00614-0 COLLEGE NANME Health Data Science COLLEGE CODE HDAT Swansea University Another institution paid the OA fee Barts Charity 2023-05-18T14:43:29.1034872 2023-04-12T11:11:21.1169491 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Health Data Science Hayley Holt 0000-0003-4153-7982 1 David A. Jolliffe 2 Mohammad Talaei 0000-0002-6901-3665 3 Sian Faustini 4 Giulia Vivaldi 0000-0003-0816-9276 5 Matthew Greenig 6 Alex G. Richter 7 Ronan Lyons 0000-0001-5225-000X 8 Christopher J. Griffiths 9 Frank Kee 10 Aziz Sheikh 11 Gwyneth Davies 0000-0003-1218-1008 12 Seif O. Shaheen 13 Adrian R. Martineau 14 63120__27417__7e333adbbc06445eb5ceb6105a8a79b7.pdf 63120.pdf 2023-05-10T16:12:03.2029285 Output 588628 application/pdf Version of Record true Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. true eng http://creativecommons.org/licenses/by/4.0/
title Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination
spellingShingle Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination
Ronan Lyons
Gwyneth Davies
title_short Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination
title_full Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination
title_fullStr Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination
title_full_unstemmed Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination
title_sort Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination
author_id_str_mv 83efcf2a9dfcf8b55586999d3d152ac6
92d69cf8519a334ced3f55142c811d95
author_id_fullname_str_mv 83efcf2a9dfcf8b55586999d3d152ac6_***_Ronan Lyons
92d69cf8519a334ced3f55142c811d95_***_Gwyneth Davies
author Ronan Lyons
Gwyneth Davies
author2 Hayley Holt
David A. Jolliffe
Mohammad Talaei
Sian Faustini
Giulia Vivaldi
Matthew Greenig
Alex G. Richter
Ronan Lyons
Christopher J. Griffiths
Frank Kee
Aziz Sheikh
Gwyneth Davies
Seif O. Shaheen
Adrian R. Martineau
format Journal article
container_title npj Vaccines
container_volume 8
container_issue 1
publishDate 2023
institution Swansea University
issn 2059-0105
doi_str_mv 10.1038/s41541-023-00614-0
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Health Data Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Health Data Science
url http://dx.doi.org/10.1038/s41541-023-00614-0
document_store_str 1
active_str 0
description Prospective population-based studies investigating associations between reactive symptoms following SARS-CoV-2 vaccination and serologic responses to vaccination are lacking. We therefore conducted a study in 9003 adults from the UK general population receiving SARS-CoV-2 vaccines as part of the national vaccination programme. Titres of combined IgG/IgA/IgM responses to SARS-CoV-2 spike (S) glycoprotein were determined in eluates of dried blood spots collected from all participants before and after vaccination. 4262 (47.3%) participants experienced systemic reactive symptoms after a first vaccine dose. Factors associating with lower risk of such symptoms included older age (aOR per additional 10 years of age 0.85, 95% CI: 0.81–0.90), male vs. female sex (0.59, 0.53–0.65) and receipt of an mRNA vaccine vs. ChAdOx1 nCoV-19 (0.29, 0.26–0.32 for BNT162b2; 0.06, 0.01–0.26 for mRNA-1273). Higher risk of such symptoms was associated with SARS-CoV-2 seropositivity and COVID-19 symptoms prior to vaccination (2.23, 1.78–2.81), but not with SARS-CoV-2 seropositivity in the absence of COVID-19 symptoms (0.94, 0.81–1.09). Presence vs. absence of self-reported anxiety or depression at enrolment associated with higher risk of such symptoms (1.24, 1.12–1.39). Post-vaccination anti-S titres were higher among participants who experienced reactive symptoms after vaccination vs. those who did not (P < 0.001). We conclude that factors influencing risk of systemic symptoms after SARS-CoV-2 vaccination include demographic characteristics, pre-vaccination SARS-CoV-2 serostatus and vaccine type. Participants experiencing reactive symptoms following SARS-CoV-2 vaccination had higher post-vaccination titres of IgG/A/M anti-S antibodies. Improved public understanding of the frequency of reactogenic symptoms and their positive association with vaccine immunogenicity could potentially increase vaccine uptake.
published_date 2023-02-25T14:43:27Z
_version_ 1766239667848478720
score 11.036815

Similar Items